{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:19:27Z","timestamp":1787019567654,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"20","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,14]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>NPM 1-mutated acute myeloid leukemia (AML) is driven by aberrant HOX\/MEIS1 expression, whose mechanistic basis remained unresolved for years. Recent paradigm-shifting studies show that mutant NPM1 organizes phase-separated nuclear condensates that concentrate transcriptional regulators at active chromatin, directly sustaining the pathogenic HOX\/MEIS1 transcriptional program. This framework explains the activity of menin-KMT2A inhibitors, recently approved by the US Food and Drug Administration, in this AML subtype and positions disruption of these assemblies as a precision strategy to eliminate oncogenic transcription.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025031880","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:01:43Z","timestamp":1775660503000},"page":"2291-2297","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Nuclear transcriptional condensates as drivers and therapeutic targets in\n                    <i>NPM1<\/i>\n                    -mutated AML"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2048-7357","authenticated-orcid":false,"given":"Hannah J.","family":"Uckelmann","sequence":"first","affiliation":[{"name":"1Department of Pediatrics, Goethe University Frankfurt, Frankfurt, Germany"},{"name":"2Frankfurt Cancer Institute, Frankfurt, Germany"},{"name":"3German Cancer Consortium, Partner Site Frankfurt\/Mainz, Heidelberg, Germany"},{"name":"4German Cancer Research Center, Heidelberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7749-7703","authenticated-orcid":false,"given":"Jayant Y.","family":"Gadrey","sequence":"additional","affiliation":[{"name":"5Department of Medicine, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2624-8576","authenticated-orcid":false,"given":"Lorenzo","family":"Brunetti","sequence":"additional","affiliation":[{"name":"6Department of Clinical and Molecular Sciences, Universit\u00e0 Politecnica delle Marche, Ancona, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"12","key":"2026051411214135100_bib1","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"D\u00f6hner","year":"2015","journal-title":"N Engl J Med"},{"issue":"12","key":"2026051411214135100_bib2","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1182\/blood-2005-05-2164","article-title":"Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations","volume":"106","author":"D\u00f6hner","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2026051411214135100_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2026051411214135100_bib4","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41408-024-01103-w","article-title":"Co-mutation landscape and its prognostic impact on newly diagnosed adult patients with NPM1-mutated de novo acute myeloid leukemia","volume":"14","author":"Yao","year":"2024","journal-title":"Blood Cancer J"},{"issue":"15","key":"2026051411214135100_bib5","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.2019004226","article-title":"NPM1-mutated acute myeloid leukemia: from bench to bedside","volume":"136","author":"Falini","year":"2020","journal-title":"Blood"},{"issue":"11","key":"2026051411214135100_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/03007995.2019.1631149","article-title":"Side effects from acute myeloid leukemia treatment: results from a national survey","volume":"35","author":"Crossnohere","year":"2019","journal-title":"Curr Med Res Opin"},{"issue":"10","key":"2026051411214135100_bib7","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1038\/s41375-022-01666-2","article-title":"Current status and future perspectives in targeted therapy of NPM1-mutated AML","volume":"36","author":"Ranieri","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"2026051411214135100_bib8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMoa041974","article-title":"Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype","volume":"352","author":"Falini","year":"2005","journal-title":"N Engl J Med"},{"key":"2026051411214135100_bib9","volume-title":"WHO Classification of Tumors Editorial Board. Hematolymphoid tumours. WHO classification of tumours series","year":"2024","edition":"5th ed."},{"issue":"5","key":"2026051411214135100_bib10","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood.2020008211","article-title":"How I diagnose and treat NPM1-mutated AML","volume":"137","author":"Falini","year":"2021","journal-title":"Blood"},{"issue":"3","key":"2026051411214135100_bib11","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","article-title":"Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance","volume":"106","author":"Alcalay","year":"2005","journal-title":"Blood"},{"issue":"12","key":"2026051411214135100_bib12","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1182\/blood-2005-05-2168","article-title":"Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance","volume":"106","author":"Verhaak","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026051411214135100_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.ccell.2018.08.005","article-title":"Mutant NPM1 maintains the leukemic state through HOX expression","volume":"34","author":"Brunetti","year":"2018","journal-title":"Cancer Cell"},{"issue":"47","key":"2026051411214135100_bib14","doi-asserted-by":"crossref","first-page":"6766","DOI":"10.1038\/sj.onc.1210760","article-title":"Hox genes in hematopoiesis and leukemogenesis","volume":"26","author":"Argiropoulos","year":"2007","journal-title":"Oncogene"},{"issue":"7","key":"2026051411214135100_bib15","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrc1885","article-title":"Nucleophosmin and cancer","volume":"6","author":"Grisendi","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2026051411214135100_bib16","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/leu.2017.30","article-title":"Biological and clinical consequences of NPM1 mutations in AML","volume":"31","author":"Heath","year":"2017","journal-title":"Leukemia"},{"issue":"5","key":"2026051411214135100_bib17","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41589-018-0021-8","article-title":"The dTAG system for immediate and target-specific protein degradation","volume":"14","author":"Nabet","year":"2018","journal-title":"Nat Chem Biol"},{"issue":"12","key":"2026051411214135100_bib18","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nmeth.4435","article-title":"Thiol-linked alkylation of RNA to assess expression dynamics","volume":"14","author":"Herzog","year":"2017","journal-title":"Nat Methods"},{"issue":"7","key":"2026051411214135100_bib19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2023021359","article-title":"Acute myeloid leukemias with UBTF tandem duplications are sensitive to menin inhibitors","volume":"143","author":"Barajas","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026051411214135100_bib20","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/leu.2015.6","article-title":"Epigenomic analysis of the HOX gene loci reveals mechanisms that may control canonical expression patterns in AML and normal hematopoietic cells","volume":"29","author":"Spencer","year":"2015","journal-title":"Leukemia"},{"issue":"10","key":"2026051411214135100_bib21","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/2159-8290.CD-24-1517","article-title":"Catalytic inhibition of KAT6\/KAT7 enhances the efficacy and overcomes primary and acquired resistance to menin inhibitors in MLL leukemia","volume":"15","author":"Gordon","year":"2025","journal-title":"Cancer Discov"},{"issue":"7789","key":"2026051411214135100_bib22","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41586-019-1835-6","article-title":"HBO1 is required for the maintenance of leukaemia stem cells","volume":"577","author":"MacPherson","year":"2020","journal-title":"Nature"},{"issue":"10","key":"2026051411214135100_bib23","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1158\/2159-8290.CD-16-0237","article-title":"Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia","volume":"6","author":"K\u00fchn","year":"2016","journal-title":"Cancer Discov"},{"issue":"6477","key":"2026051411214135100_bib24","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1126\/science.aax5863","article-title":"Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia","volume":"367","author":"Uckelmann","year":"2020","journal-title":"Science"},{"key":"2026051411214135100_bib25","doi-asserted-by":"crossref","first-page":"e46667","DOI":"10.7554\/eLife.46667","article-title":"Chromatin-bound CRM1 recruits SET-Nup214 and NPM1c onto HOX clusters causing aberrant HOX expression in leukemia cells","volume":"8","author":"Oka","year":"2019","journal-title":"eLife"},{"issue":"3","key":"2026051411214135100_bib26","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1158\/2159-8290.CD-22-0366","article-title":"Mutant NPM1 directly regulates oncogenic transcription in acute myeloid leukemia","volume":"13","author":"Uckelmann","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"2026051411214135100_bib27","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1158\/2159-8290.CD-22-0424","article-title":"Mutant NPM1 hijacks transcriptional hubs to maintain pathogenic gene programs in acute myeloid leukemia","volume":"13","author":"Wang","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"2026051411214135100_bib28","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nrm.2017.7","article-title":"Biomolecular condensates: organizers of cellular biochemistry","volume":"18","author":"Banani","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"2026051411214135100_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41580-020-0272-6","article-title":"The nucleolus as a multiphase liquid condensate","volume":"22","author":"Lafontaine","year":"2021","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"7","key":"2026051411214135100_bib30","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2018.10.042","article-title":"Transcription factors activate genes through the phase-separation capacity of their activation domains","volume":"175","author":"Boija","year":"2018","journal-title":"Cell"},{"issue":"1","key":"2026051411214135100_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.devcel.2020.09.005","article-title":"Biomolecular condensates and gene activation in development and disease","volume":"55","author":"Sabari","year":"2020","journal-title":"Dev Cell"},{"issue":"1","key":"2026051411214135100_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cell.2017.02.007","article-title":"A phase separation model for transcriptional control","volume":"169","author":"Hnisz","year":"2017","journal-title":"Cell"},{"issue":"6400","key":"2026051411214135100_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1126\/science.aar4199","article-title":"Mediator and RNA polymerase II clusters associate in transcription-dependent condensates","volume":"361","author":"Cho","year":"2018","journal-title":"Science"},{"key":"2026051411214135100_bib34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.trecan.2023.05.006","article-title":"Onco-condensates: formation, multi-component organization, and biological functions","volume":"9","author":"Xu","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"2026051411214135100_bib35","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.1038\/s41467-023-41655-2","article-title":"Defining the condensate landscape of fusion oncoproteins","volume":"14","author":"Tripathi","year":"2023","journal-title":"Nat Commun"},{"issue":"25","key":"2026051411214135100_bib36","doi-asserted-by":"crossref","first-page":"7118","DOI":"10.1016\/j.cell.2025.10.010","article-title":"Disparate leukemia mutations converge on nuclear phase-separated condensates","volume":"188","author":"Datar","year":"2025","journal-title":"Cell"},{"issue":"suppl 1","key":"2026051411214135100_bib37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2025-865","article-title":"Wildtype NUP98 cooperates with NPM1c to drive oncogenic transcription [abstract]","volume":"146","author":"Gama","year":"2025","journal-title":"Blood"},{"issue":"2","key":"2026051411214135100_bib38","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41594-020-00550-w","article-title":"Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression","volume":"28","author":"Terlecki-Zaniewicz","year":"2021","journal-title":"Nat Struct Mol Biol"},{"issue":"7868","key":"2026051411214135100_bib39","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41586-021-03662-5","article-title":"Phase separation drives aberrant chromatin looping and cancer development","volume":"595","author":"Ahn","year":"2021","journal-title":"Nature"},{"issue":"4","key":"2026051411214135100_bib40","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2159-8290.CD-21-0674","article-title":"Phase separation mediates NUP98 fusion oncoprotein leukemic transformation","volume":"12","author":"Chandra","year":"2022","journal-title":"Cancer Discov"},{"issue":"8","key":"2026051411214135100_bib41","doi-asserted-by":"crossref","first-page":"112884","DOI":"10.1016\/j.celrep.2023.112884","article-title":"Phase-separated nuclear bodies of nucleoporin fusions promote condensation of MLL1\/CRM1 and rearrangement of 3D genome structure","volume":"42","author":"Oka","year":"2023","journal-title":"Cell Rep"},{"issue":"2","key":"2026051411214135100_bib42","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1172\/JCI129126","article-title":"Menin inhibitor MI-3454 induces remission in MLL1-rearranged and NPM1-mutated models of leukemia","volume":"130","author":"Klossowski","year":"2020","journal-title":"J Clin Invest"},{"issue":"2","key":"2026051411214135100_bib43","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.35332","article-title":"Targeting the menin-KMT2A interaction in leukemia: lessons learned and future directions","volume":"158","author":"Perner","year":"2026","journal-title":"Int J Cancer"},{"issue":"9","key":"2026051411214135100_bib44","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.trecan.2025.06.002","article-title":"Advances in menin inhibition in acute myeloid leukemia","volume":"11","author":"Boussi","year":"2025","journal-title":"Trends Cancer"},{"issue":"7954","key":"2026051411214135100_bib45","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/s41586-023-05755-9","article-title":"MEN1 mutations mediate clinical resistance to menin inhibition","volume":"615","author":"Perner","year":"2023","journal-title":"Nature"},{"issue":"24","key":"2026051411214135100_bib46","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-11-750158","article-title":"A phase 1 clinical trial of single-agent selinexor in acute myeloid leukemia","volume":"129","author":"Garzon","year":"2017","journal-title":"Blood"},{"issue":"22","key":"2026051411214135100_bib47","doi-asserted-by":"crossref","first-page":"5938","DOI":"10.1182\/bloodadvances.2022007563","article-title":"Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML","volume":"6","author":"Pianigiani","year":"2022","journal-title":"Blood Adv"},{"key":"2026051411214135100_bib48","doi-asserted-by":"crossref","first-page":"19.23.1","DOI":"10.1002\/cpps.51","article-title":"BioID: a screen for protein-protein interactions","volume":"91","author":"Roux","year":"2018","journal-title":"Curr Protoc Protein Sci"},{"key":"2026051411214135100_bib49","doi-asserted-by":"crossref","first-page":"eadm7435","DOI":"10.1126\/sciadv.adm7435","article-title":"Specific protein-RNA interactions are mostly preserved in biomolecular condensates","volume":"10","author":"de Vries","year":"2024","journal-title":"Sci Adv"},{"issue":"2","key":"2026051411214135100_bib50","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.cell.2017.03.022","article-title":"An approach to spatiotemporally resolve protein interaction networks in living cells","volume":"169","author":"Lobingier","year":"2017","journal-title":"Cell"},{"issue":"25","key":"2026051411214135100_bib51","doi-asserted-by":"crossref","first-page":"7079","DOI":"10.1016\/j.cell.2024.09.040","article-title":"Light-induced targeting enables proteomics on endogenous condensates","volume":"187","author":"Lee","year":"2024","journal-title":"Cell"},{"issue":"13","key":"2026051411214135100_bib52","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022016033","article-title":"Proteomic and phosphoproteomic landscapes of acute myeloid leukemia","volume":"140","author":"Kramer","year":"2022","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/20\/2291\/2519424\/blood_bld-2025-031880-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/20\/2291\/2519424\/blood_bld-2025-031880-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T15:21:54Z","timestamp":1778772114000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/20\/2291\/567342\/Nuclear-transcriptional-condensates-as-drivers-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":52,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026,5,14]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025031880","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,14]]},"published":{"date-parts":[[2026,5,14]]}}}